Your session is about to expire
← Back to Search
Cancer Vaccine
Vaccine Therapy for Melanoma
Phase 1
Waitlist Available
Research Sponsored by Herbert Irving Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically confirmed metastatic non-resectable cutaneous, subcutaneous, or lymph node malignant melanoma
Lesion(s) must be accessible to percutaneous injection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing a vaccine to see if it can help treat patients with metastatic melanoma.
Who is the study for?
This trial is for adults over 18 with metastatic melanoma that hasn't spread to the bone marrow. Participants must have a life expectancy of more than 3 months, no severe heart conditions or other cancers in the past 2 years (except certain skin/cervical cancers), and no major health issues. They should not be pregnant/nursing and must use contraception.Check my eligibility
What is being tested?
The study is testing a vaccine therapy's ability to stimulate the immune system to fight metastatic melanoma. It's an early-phase trial, meaning it's one of the first times this treatment is being tested in humans to evaluate its safety and how well it works.See study design
What are the potential side effects?
Potential side effects are not detailed here but may include typical vaccine-related reactions such as soreness at injection site, fever, fatigue, allergic reactions due to egg components in the vaccine, and possibly others depending on individual responses.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My melanoma cannot be removed by surgery and has spread to my skin, fat, or lymph nodes.
Select...
My cancer can be reached with a needle through the skin.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Herbert Irving Comprehensive Cancer CenterLead Sponsor
33 Previous Clinical Trials
929 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,153 Total Patients Enrolled
Howard L. Kaufman, MDStudy ChairHerbert Irving Comprehensive Cancer Center
3 Previous Clinical Trials
72 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am younger than 18 years old.My kidney function is reduced with high creatinine or low clearance.I haven't had any cancer other than stage I cervical or basal cell skin cancer in the last 2 years.I have limited ability to care for myself.I do not have serious heart conditions like heart failure or recent heart attacks.I have a lung condition like COPD.I do not have immune conditions like eczema, HIV, autoimmune diseases, leukemia, lymphoma, skin diseases, open wounds, immunosuppression, active infections, or severe egg allergies.I have not had vaccinia virus therapy or been on steroids/immunosuppressives recently.My melanoma cannot be removed by surgery and has spread to my skin, fat, or lymph nodes.My cancer can be reached with a needle through the skin.It has been over 6 weeks since my last major cancer treatment.I have seizures that are currently not under control.I have untreated brain tumors or cancer spread to the lining of my brain.I have fluid buildup in my abdomen or around my lungs.I have a severe blood clotting disorder or serious liver issues.I had brain metastases treated and now have no signs of disease or swelling on scans.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How would you rate the security of this treatment for individuals?
"Accordingly, the safety rating for this treatment is assessed to be a level 1 due to it being in a Phase 1 trial with sparse data on both efficacy and security."
Answered by AI
Are there any vacancies to join this medical experiment?
"This clinical trial, initially posted on August 1st 2001 and last edited December 17th 2013, is not actively seeking participants. Despite this inactivity there are still 757 medical studies currently recruiting patients."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger